Johnson & JohnsonJNJEarnings & Financial Report
Johnson & Johnson (J&J) is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey, and publicly traded on the New York Stock Exchange. Its common stock is a component of the Dow Jones Industrial Average, and the company is ranked No. 48 on the 2025 Fortune 500 list of the largest United States corporations. In 2025, the company was ranked 42th in the Forbes Global 2000.
JNJ Q4 FY2025 Key Financial Metrics
Revenue
$24.6B
Gross Profit
$16.6B
Operating Profit
$5.0B
Net Profit
$5.1B
Gross Margin
67.6%
Operating Margin
20.2%
Net Margin
20.8%
YoY Growth
9.1%
EPS
$2.08
Johnson & Johnson Q4 FY2025 Financial Summary
Johnson & Johnson reported revenue of $24.6B (up 9.1% YoY) for Q4 FY2025, with a net profit of $5.1B (up 49.1% YoY) (20.8% margin). Cost of goods sold was $8.0B, operating expenses totaled $11.6B.
Key Financial Metrics
| Total Revenue | $24.6B |
|---|---|
| Net Profit | $5.1B |
| Gross Margin | 67.6% |
| Operating Margin | 20.2% |
| Report Period | Q4 FY2025 |
Revenue Breakdown
Johnson & Johnson Q4 FY2025 revenue of $24.6B breaks down across 10 segments, led by Other at $14.2B (57.7% of total).
| Segment | Revenue | % of Total |
|---|---|---|
| Other | $14.2B | 57.7% |
| Immunology | $2.5B | 10.2% |
| Orthopaedics | $1.5B | 6.2% |
| Neuroscience | $1.4B | 5.9% |
| Cardiovascular | $1.4B | 5.6% |
| Surgery | $1.1B | 4.4% |
| Pulmonary Hypertension | $865.0M | 3.5% |
| Cardiovascular Metabolism Other | $794.0M | 3.2% |
| Vision | $531.0M | 2.2% |
| Infectious Diseases | $303.0M | 1.2% |
Johnson & Johnson Revenue by Segment — Quarterly Trend
Johnson & Johnson revenue by segment across the last 4 reported quarters, showing how each business line (such as Other and Immunology) has evolved quarter over quarter.
| Segment | Q4 FY2025 | Q3 FY2025 | Q2 FY2025 | Q1 FY2025 |
|---|---|---|---|---|
| Other | $14.2B | $11.6B | $8.8B | $11.8B |
| Immunology | $2.5B | $2.7B | $2.5B | — |
| Orthopaedics | $1.5B | $1.4B | $1.4B | $1.4B |
| Neuroscience | $1.4B | — | $1.4B | $968.0M |
| Cardiovascular | $1.4B | — | $1.4B | — |
Johnson & Johnson Annual Revenue by Year
Johnson & Johnson annual revenue history includes year-by-year totals (for example, 2025 revenue was $94.2B).
Johnson & Johnson Quarterly Revenue & Net Profit History
Johnson & Johnson results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $24.6B | +9.1% | $5.1B | 20.8% |
| Q3 FY2025 | $24.0B | +6.8% | $5.2B | 21.5% |
| Q2 FY2025 | $23.7B | +5.8% | $5.5B | 23.3% |
| Q1 FY2025 | $21.9B | +2.4% | $11.0B | 50.2% |
| Q4 FY2024 | $22.5B | +5.5% | $3.4B | 15.2% |
| Q3 FY2024 | $22.5B | -12.0% | $2.7B | 12.0% |
| Q2 FY2024 | $22.4B | -9.3% | $4.7B | 20.9% |
| Q1 FY2024 | $21.4B | -9.8% | $3.3B | 15.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $21.38B | $22.45B | $22.47B | $22.52B | $21.89B | $23.74B | $23.99B | $24.56B |
| YoY Growth | -9.8% | -9.3% | -12.0% | 5.5% | 2.4% | 5.8% | 6.8% | 9.1% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $171.97B | $181.09B | $178.29B | $180.10B | $193.67B | $193.39B | $192.82B | $199.21B |
| Liabilities | $101.95B | $109.55B | $108.13B | $108.61B | $115.56B | $114.92B | $113.54B | $117.67B |
| Equity | $70.02B | $71.54B | $70.16B | $71.49B | $78.11B | $78.47B | $79.28B | $81.54B |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $3.66B | $5.63B | $7.99B | $6.98B | $4.17B | $3.88B | $9.17B | $7.31B |